Thursday, July 30, 2015

Ciclofilin Pharma’s lead antiviral drug reduces liver HBV DNA

Ciclofilin Pharma’s lead antiviral drug reduces liver HBV DNA

July 28, 2015 by · Leave a Comment 

Tweet Closely-held Ciclofilin Pharmaceuticals has reported that its lead antiviral drug candidate demonstrated significantly reduced liver hepatitis B virus (HBV) DNA in a transgenic mouse model. The National Institute of Allergy and Infectious Diseases, one of the centers within the NIH conducted the study. Ciclofilin’s CPI-431-32 is a proprietary cyclophilin inhibiting molecule that targets the […]

Ciclofilin demonstrates anti-fibrotic activity with CPI-431-32

Ciclofilin demonstrates anti-fibrotic activity with CPI-431-32

June 24, 2015 by · Leave a Comment 

Tweet Closely-held Ciclofilin Pharmaceuticals’ lead antiviral drug has demonstrated anti-fibrotic activity in a liver fibrosis animal model. CPI-431-32 is a proprietary cyclophilin antagonist that potently inhibits hepatitis B virus (HBV). It acts primarily by inhibiting HBV’s ability to hijack and utilize the host cell protein, cyclophilin, to propagate infection. In vitro experiments conducted in collaboration […]

Ciclofilin to present HBV/HIV/HCV co-infection data at EASL

Ciclofilin to present HBV/HIV/HCV co-infection data at EASL

February 17, 2015 by · Leave a Comment 

Tweet Closely-held Ciclofilin Pharmaceuticals’ abstract entitled, “Novel Cyclophilin Inhibitor CPI-431-32 Shows Broad Spectrum Antiviral Activity By Blocking Replication of HCV, HBV and HIV-1 Viruses,” will be presented at the European Association for the Study of the Liver (EASL) to be held April 22-26 in Vienna. The company’s CPI-431-32 targets and inhibits a host cellular enzyme […]

ILJIN withdraws damage claims against Isotechnika

ILJIN withdraws damage claims against Isotechnika

January 15, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) announced that ILJIN Life Sciences of South Korea has formally notified Isotechnika and the arbitral tribunal that it has withdrawn all claims for damages in the parties’ pending arbitration arising from a development, distribution and license agreement. As previously reported, the agreement was declared to be in “full force and effect” […]

Isotechnika’s NICAMs effective against Hepatitis C virus

Isotechnika’s NICAMs effective against Hepatitis C virus

December 6, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) has announced positive anti-hepatitis C virus (HCV) results from the second round of in vitro testing of its cyclophilin antagonist molecules (NICAMs) carried out by the NIH’s National Institute of Allergy and Infectious Diseases. Several NICAM compounds were tested for cross genotype activity using quantitative polymerase chain reaction in HCV replicons, […]

Isotechnika receives partial award in ICC arbitration

Isotechnika receives partial award in ICC arbitration

November 30, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) has received a partial award from the International Chamber of Commerce Court of Arbitration regarding its right to terminate a development, distribution and license (DDL) agreement with ILJIN Life Sciences of South Korea. The partial award provides that the DDL has not been terminated and the company’s contractual relationship with ILJIN […]

FDA clears Isotechnika for Phase 3 voclosporin trial

FDA clears Isotechnika for Phase 3 voclosporin trial

November 26, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) has received permission from the FDA to commence the first of two planned Phase 3 kidney transplant trials for its lead product candidate, voclosporin, under a special protocol assessment (SPA) from the FDA. The SPA was received after the FDA reviewed Isotechnika’s Phase 2b data and evaluated the proposed Phase 3 […]

Isotechnika gets added Canadian funding for NICAMs

Isotechnika gets added Canadian funding for NICAMs

July 17, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) has received approval for additional funding from the National Research Council Industrial Research Assistance Program (NRC-IRAP) for its Non-Immunosuppressive Cyclosporin Analog Molecules (NICAM) program. NRC-IRAP previously assisted Isotechnika in the discovery of a series of NICAMs that were shown to be potent inhibitors of a class of proteins called cyclophilins. Research […]

Isotechnika partner completes enrolment in Phase 3 uveitis study

Isotechnika partner completes enrolment in Phase 3 uveitis study

July 9, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) partner, Lux Biosciences, has completed patient enrolment in its Phase 3 clinical study using voclosporin (branded as Luveniq) for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability. Lux anticipates that data from the Phase 3 study will be available early in the first quarter of […]

NIH agency to evaluate Isotechnika’s NICAMs

NIH agency to evaluate Isotechnika’s NICAMs

April 11, 2012 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX: ISA) has signed a three-year Non-Clinical Evaluation Agreement with the NIH’s National Institute of Allergy and Infectious Diseases (NIAID). Under the accord, NIAID-funded contractors will evaluate the company’s portfolio of non-immunosuppressive cyclosporine analogue molecules (NICAMs) as anti-viral agents. Isotechnika’s NICAM portfolio will be tested through NIAID’s preclinical services program for use […]

Next Page »

Email Newsletters with Constant Contact
Google+